Balancing fairness and efficiency in dynamic vaccine allocation during major infectious disease outbreaks
- PMID: 39779729
- PMCID: PMC11711769
- DOI: 10.1038/s41598-024-84027-6
Balancing fairness and efficiency in dynamic vaccine allocation during major infectious disease outbreaks
Abstract
The outbreak of novel infectious diseases presents major public health challenges, highlighting the urgency of accelerating vaccination efforts to reduce morbidity and mortality. Vaccine allocation has become a crucial societal concern. This paper introduces a dynamic vaccine allocation model that considers demand uncertainty and vaccination willingness, focusing on the trade-off between fairness and efficiency. We develop a multi-period dynamic vaccine allocation model, evaluating optimal strategies over different periods. The model addresses structural differences among vaccination groups, strategy selection, dynamic demand, and vaccination willingness. Our findings suggest that prioritizing efficiency in the initial outbreak stages may lead to inequitable distribution, causing adverse social impacts, while overemphasizing fairness can undermine overall utility. Therefore, we propose a dynamic optimization-based strategy balancing fairness and efficiency at different pandemic stages. Our results indicate that allocation strategies should shift from efficiency to fairness as the pandemic evolves to enhance vaccine utility. Additionally, macro-level interventions like reducing free-rider behavior and increasing vaccination convenience can improve total vaccine utility. This study offers new perspectives and methodologies for dynamic vaccine allocation, highlighting the trade-off between fairness and efficiency, providing crucial insights for policy formulation and pandemic response.
Keywords: Decision preference; Dynamic vaccine allocation; Major Novel Infectious diseases; Vaccination willingness.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures








Similar articles
-
Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea.J Korean Med Sci. 2021 Jun 14;36(23):e166. doi: 10.3346/jkms.2021.36.e166. J Korean Med Sci. 2021. PMID: 34128597 Free PMC article.
-
Evaluation of the United States COVID-19 vaccine allocation strategy.PLoS One. 2021 Nov 17;16(11):e0259700. doi: 10.1371/journal.pone.0259700. eCollection 2021. PLoS One. 2021. PMID: 34788345 Free PMC article.
-
Optimizing COVID-19 vaccine allocation considering the target population.Front Public Health. 2023 Jan 6;10:1015133. doi: 10.3389/fpubh.2022.1015133. eCollection 2022. Front Public Health. 2023. PMID: 36684954 Free PMC article.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
Coronavirus vaccine development: from SARS and MERS to COVID-19.J Biomed Sci. 2020 Dec 20;27(1):104. doi: 10.1186/s12929-020-00695-2. J Biomed Sci. 2020. PMID: 33341119 Free PMC article. Review.
References
-
- Yarmand, H., Ivy, J. S., Denton, B. & Lloyd, A. L. Optimal two-phase vaccine allocation to geographically different regions under uncertainty. Eur. J. Oper. Res.233, 208–219 (2014).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical